摘要
目的:系统评价马来酸曲美布汀治疗肠易激综合征的临床效果及安全性。方法:计算机检索中文科技期刊数据库(VIP)、万方数据库(Wanfang Data)、中国学术期刊全文数据库(CNKI)、Pubmed和Cochrane library,收集有关于马来酸曲美布汀治疗肠易激综合征的随机对照试验,使用Cochrane随机对照试验偏倚风险评估工具对纳入研究进行方法学质量评价,并使用Rev Man5.3软件进行统计分析。结果:共纳入18个RCT,1587例患者。Meta分析结果显示,(1)马来酸曲美布汀能改善肠易激综合征患者临床症状,与其他治疗药物相比,在症状改善方面差异无统计学意义[OR=0.97,P>0.05,95%CI(0.55,1.72)];(2)马来酸曲美布汀与其他药物联合应用较其单纯治疗肠易激综合征在症状改善方面优势明显,差异有统计学意义[OR=4.35,P<0.01,95%CI(3.14,6.03)];(3)马来酸曲美布汀与其他药物联合应用较其单纯治疗肠易激综合征在治疗期间发生药物不良反应的差异无统计学意义[OR=0.94,P>0.05,95%CI(0.50,1.78)]。结论:马来酸曲美布汀治疗IBS有一定效果,但疗效是否更好仍然缺乏有力证据,与其他药物联合治疗时,临床疗效更显著且未明显增加不良反应,可作为治疗肠易激综合征的一种选择。本次研究纳入文献质量一般,建议将本次Meta分析结果作为临床应用证据时谨慎些。
Objective： To systemically assess the therapeutic effect and safety of the Trimebutine Maleate on irritable bowel syndrome（IBS）. Method： Firstly, the randomized controlled trials of the Trimebutine Maleate on IBS were searched, collected and screened.Secondly, the quality of the included trials was assessed through Cochrane tool for assessing risk of bias.Finally, a Meta-analysis was performed through the Software RevMan5.3 to systemically evaluate the included studies.Result： 18 articles were included in this study.1587 cases were cumulated in the research.Meta-analyses showed that： （1）The Trimebutine Maleate can improve clinical symptoms of IBS.Compared with other treatments, there were no significant statistical differences in symptom improvement between the two groups[OR=0.97, P〉0.05, 95%CI（0.55, 1.72）].（2） There were significant statistical differences in symptom improvement between the two groups[OR=4.35, P〈0.01, 95%CI（3.14, 6.03）].（3）There were no significant statistical differences of adverse drug reaction during treatment between the two groups[OR=0.94, P〉0.05, 95%CI（0.50, 1.78）].Conclusion： Trimebutine Maleate has a certain effect in the treatment of IBS.But whether the effect is better still lacks of strong evidence.When Trimebutine Maleate combined with other drugs, its clinical efficacy was more significant and doesn＇t significantly increase adverse reactions. Trimebutine Maleate as an option for treatment of irritable bowel syndrome.This study included literature quality are not fine enough.On this account, it is recommended that the Meta-analysis of clinical evidence was applied as a result need to be cautious.
出处
《中外医学研究》
2017年第10期11-15,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
